Why is Godavari Drugs falling/rising?

As of 14-Jul, Godavari Drugs Ltd is currently priced at 88.30, reflecting a slight increase of 0.1 (0.11%). Despite this minor uptick, the stock has shown a negative performance trend, underperforming its sector by 0.79% today. It is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment. Over the past week, the stock has decreased by 1.89%, and it has seen a significant decline of 19.25% year-to-date. The company has also reported a drop in delivery volume, which fell by 17.23% against the 5-day average, suggesting reduced investor interest. While the stock is trading at a discount compared to its peers, it has experienced a 14.73% decline in returns over the past year, coupled with a 22.1% decrease in profits, which raises concerns about its long-term viability.
In the broader market context, Godavari Drugs has underperformed relative to the Sensex, which has gained 5.27% year-to-date, highlighting the stock's struggles in a generally positive market environment. The stock's weak long-term fundamentals, including a high Debt to EBITDA ratio of 3.15 times and a significant decline in PAT and net sales, further exacerbate its challenges. The company has shown a 13.98% CAGR growth in operating profits over the last five years, but this is overshadowed by its recent negative performance and inability to service debt effectively. Overall, the combination of weak investor participation, poor financial results, and unfavorable comparisons to the benchmark suggests that Godavari Drugs is facing significant headwinds.